March 6, 2020 / 11:52 AM / 25 days ago

BRIEF-Kancera Reports Positive Results From Final Part Of Phase Ib Program For KAND567

March 6 (Reuters) - Kancera AB:

* REPORTS POSITIVE RESULTS FROM FINAL PART OF PHASE IB PROGRAM FOR KAND567

* RESULTS FROM PHASE IB PROGRAM FOR KAND567 SHOW THAT DRUG CANDIDATE IS WELL-TOLERATED BY INTRAVENOUS ADMINISTRATION

* WILL NOW COMPILE APPLICATION FOR PERMISSION TO START PHASE II CLINICAL TRIAL IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below